Clinical Research Directory
Browse clinical research sites, groups, and studies.
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
Sponsor: Todd Sweberg
Summary
The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock. The main questions it aims to answer are: * To evaluate the change in blood pressure or reduction of vasoactive requirements (norepinephrine equivalent dosing) after initiating Angiotensin II * To establish the safety and tolerability of Angiotensin-II in pediatric patients Participants will receive Angiotensin-II in addition to standard of care therapy for vasodilatory shock. * The study team will then monitor the patient's vital signs, blood work, and for any potential side effects from the drug. * An ultrasound will be performed to look at blood flow through the kidney in the setting of vasodilatory shock. * A follow up phone call to check in with the patient will be performed 28 days after enrollment.
Official title: An Open-Label, Single-Center Study of Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension Despite Receiving Fluid Therapy and Vasoactive Therapy
Key Details
Gender
All
Age Range
0 Days - 18 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-09-09
Completion Date
2030-06
Last Updated
2025-10-08
Healthy Volunteers
No
Conditions
Interventions
Angiotensin-II
Angiotensin-II will be given per the titration protocol.
Locations (2)
Cohen Children's Medical Center of Northwell Health
New Hyde Park, New York, United States
Cohen Children's Medical Center
Queens, New York, United States